Given these particular strengths, Chang predicts that acting as an Asian agent for technologies that are already partially developed will become the Taiwanese biotechnology industry's principal business model over the next 10-15 years.
張子文預估，這種以代理亞洲市場為著眼點的「中間切入型研發」模式，將是台灣生技界在未來十到十五年內的主要經營模式。